Comments on “Efficacy and safety of different doses of apremilast in mild to moderate psoriasis”

Nitin Chintaman Gawari, Aishwarya Rudrabhate, Abhijeet Tilak, B. T. Rane · 2026

Read Comments on “Efficacy and safety of different doses of apremilast in mild to moderate psoriasis” by Nitin Chintaman Gawari, Aishwarya Rudrabhate, Abhijeet Tilak, B. T. Rane (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610763.txt.

Description

Nitin Gawari and three co-authors comment on a trial comparing two doses of a psoriasis drug, in this 2026 letter. The drug, apremilast, is a tablet used for mild to moderate psoriasis, a skin disease of red, scaly patches. The trial found the higher dose, thirty milligrams twice a day, and the lower dose broadly similar on the main measures, and both were judged effective.

The letter writers point to gaps hidden inside that verdict of sameness. On the strictest measure, near-complete skin clearing, the higher dose helped about twenty-four in a hundred patients against seventeen on the lower dose. Doctor-rated clearing showed a similar edge. None of the gaps reached statistical proof, but they might matter to patients choosing a dose. The letter asks readers to weigh the size of a difference, not only whether it cleared a significance bar.

Catalog record

CREATORNitin Chintaman Gawari, Aishwarya Rudrabhate, Abhijeet Tilak, B. T. Rane
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13610763

Browse the full library · About the Tower of Babel